Familial Hypercholesterolemia and Atherosclerosis: Animal Models and Therapeutic Advances

Suowen Xu; Jianping Weng

doi:10.1016/j.tem.2020.02.007

Familial Hypercholesterolemia and Atherosclerosis: Animal Models and Therapeutic Advances

Trends Endocrinol Metab. 2020 May;31(5):331-333. doi: 10.1016/j.tem.2020.02.007. Epub 2020 Mar 16.

Authors

Suowen Xu¹, Jianping Weng²

Affiliations

¹ Department of Endocrinology and Metabolism, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, China. Electronic address: sxu1984@ustc.edu.cn.
² Department of Endocrinology and Metabolism, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, China.

PMID: 32305096
DOI: 10.1016/j.tem.2020.02.007

Abstract

Familial hypercholesterolemia (FH), mainly arising from loss-of-function mutation of the low-density lipoprotein receptor (LDLR), is a life-threatening inherited cardiometabolic disorder with limited therapies. In a recent study, Zhao et al. created a new model of FH and demonstrate that LDLR gene editing protects against both FH and atherosclerosis.

Keywords: LDL receptor; atherosclerosis; familial hypercholesterolemia; therapy.

Publication types

Review

MeSH terms

Animals
Atherosclerosis / genetics
Atherosclerosis / prevention & control*
Disease Models, Animal*
Gene Editing*
Humans
Hyperlipoproteinemia Type II / genetics
Hyperlipoproteinemia Type II / prevention & control*
Receptors, LDL / genetics*

Substances

Receptors, LDL